



Japan Council for Quality Health Care

Project to Collect Medical Near-Miss/
Adverse Event Information

Medical Safety Information


No.2, January 2007

Bone marrow suppression due to antirheumatic (Methotrexate) overdose

Cases of bone marrow suppression occurring due to overdose of antirheumatic (Methotrexate) have been reported (information collection period, from October 1, 2004 to September 30, 2006; the information included in "Medical Adverse Event Information to Be Shared" in the 3rd and 7th Quarterly Reports).

**Methotrexate,
prescribed as an anti-rheumatic drug,
requires drug holidays.**

《Administration example》



◆ Methotrexate is also a drug used for tumor treatment.

Bone marrow suppression due to antirheumatic (Methotrexate) overdose

Case

The patient properly self-managed the administration of an antirheumatic (Methotrexate) two days a week, for a total of three times within the week, even after hospitalization. After treatment, while the patient could not self-manage it on his own, the drug administration was handled by the hospital staffs. However, they prepared it as everyday administration, resulting in overdose.


Methotrexate products used as antirheumatic drugs.

- Methotrexate tablets 2mg
- Metolate tablets 2mg
- Trexamette 2mg
- Methotrexate 2mg
- Rheumatrex capsules 2mg

* As part of the Project to Collect Medical Near-Miss/Adverse Event Information (a Ministry of Health, Labour and Welfare grant project), this medical safety information was prepared based on the cases collected in the Project as well as on opinions of "Comprehensive Evaluation Panel" to prevent occurrence and recurrence of medical adverse events. See quarterly reports and annual reports posted on the Japan Council for Quality Health Care website for details of the Project. <http://www.med-safe.jp/>

* Accuracy of information was ensured at the time of preparation but can not be guaranteed in the future.

* This information is neither for limiting the discretion of healthcare providers nor for imposing certain obligations or responsibilities on them.



Division of Adverse Event Prevention
Japan Council for Quality Health Care

1-4-17 Misakicho, Chiyoda-ku, Tokyo 101-0061 JAPAN
Direct Tel:+81-3-5217-0252 Direct Fax:+81-3-5217-0253
<http://www.jcqhc.or.jp/html/index.htm>